Latest & greatest articles for ondansetron

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ondansetron or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ondansetron and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ondansetron

1. Risks and benefits of ondansetron for children with acute gastroenteritis

Risks and benefits of ondansetron for children with acute gastroenteritis Signal - Risks and benefits of ondansetron for children with acute gastroenteritis Dissemination Centre Discover Portal NIHR DC Discover Risks and benefits of ondansetron for children with acute gastroenteritis Published on 7 February 2017 Giving ondansetron to children with acute gastroenteritis can stop vomiting, reduce the risk of oral rehydration treatment failing, and reduce the chances of needing intravenous (...) rehydration. But the drug can worsen diarrhoea symptoms. This systematic review looked for evidence about ondansetron’s effectiveness in stopping vomiting and for any impact on diarrhoea or other side effects. Only five out of the 10 included trials reported on diarrhoea related outcomes and they all used different outcome measures so the results could not be combined. This means that although diarrhoea is a recognised side-effect, it is still not known to what extent children given ondansetron may

NIHR Dissemination Centre2018

2. Ondansetron

Ondansetron Top results for ondansetron - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ondansetron The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Risks and benefits of ondansetron for children with acute gastroenteritis

Risks and benefits of ondansetron for children with acute gastroenteritis NIHR DC | Signal - Risks and benefits of ondansetron for children with acute gastroenteritis Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Risks and benefits of ondansetron for children with acute gastroenteritis Published on 7 February 2017 Giving ondansetron to children with acute gastroenteritis can stop vomiting, reduce the risk of oral rehydration treatment failing, and reduce the chances (...) of needing intravenous rehydration. But the drug can worsen diarrhoea symptoms. This systematic review looked for evidence about ondansetron’s effectiveness in stopping vomiting and for any impact on diarrhoea or other side effects. Only five out of the 10 included trials reported on diarrhoea related outcomes and they all used different outcome measures so the results could not be combined. This means that although diarrhoea is a recognised side-effect, it is still not known to what extent children

NIHR Dissemination Centre2018

4. Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial

Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial 29463461 2018 02 21 1097-6760 2018 Feb 17 Annals of emergency medicine Ann Emerg Med Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial. S0196-0644(18)30029-5 10.1016/j.annemergmed.2018.01.016 We compare aromatherapy with inhaled isopropyl alcohol versus oral ondansetron for treating (...) nausea among emergency department (ED) patients not requiring immediate intravenous access. In a randomized, blinded, placebo-controlled trial, we enrolled a convenience sample of adults presenting to an urban tertiary care ED with chief complaints including nausea or vomiting. We randomized subjects to 1 of 3 arms: inhaled isopropyl alcohol and 4 mg oral ondansetron, inhaled isopropyl alcohol and oral placebo, and inhaled saline solution placebo and 4 mg oral ondansetron. The primary outcome

EvidenceUpdates2018

5. The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery

The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery 28806217 2017 08 14 2017 08 18 1532-8651 42 5 2017 Sep/Oct Regional anesthesia and pain medicine Reg Anesth Pain Med The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery. 669-673 10.1097/AAP.0000000000000642 Multiple animal studies suggest that ondansetron ameliorates opioid-induced hyperalgesia and tolerance (...) . In this study, we aimed to determine if the administration of ondansetron prior to spinal anesthesia would have an effect on intrathecal opioid-induced acute opioid tolerance, postoperative pain, and analgesic requirements in patients undergoing cesarean delivery with spinal anesthesia. Eighty-six patients undergoing elective cesarean delivery were recruited and randomly allocated to receive either 8 mg intravenous ondansetron (n = 44) or placebo (n = 42) in a prospective, double-blind design. All patients

EvidenceUpdates2017

6. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2D6</em> genotype and use of ondansetron and tropisetron.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team (...) NGC:011251 2017 Aug NEATS Assessment Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez JAG, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 Aug;102(2):213-8. [30 references] This is the current

National Guideline Clearinghouse (partial archive)2017

8. Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines

Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Ondansetron for Gastroenteritis: Clinical Effectiveness and Guidelines Published on: October 7, 2015 Project Number: RA0811-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical (...) effectiveness of ondansetron for children with acute gastroenteritis? What is the clinical effectiveness of ondansetron for adults with acute gastroenteritis? What are the evidence-based guidelines for the use of ondansetron for patients with acute gastroenteritis? Key Message Four systematic reviews, three randomized controlled trials, five non-randomized studies, and two evidence-based guidelines were identified regarding ondansetron use for patients with acute gastroenteritis. Tags antiemetics

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

10. Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo

Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo 24818542 2014 12 02 2015 04 20 2014 12 02 1097-6760 64 5 2014 Nov Annals of emergency medicine Ann Emerg Med Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. 526-532.e1 10.1016/j.annemergmed.2014.03.017 S0196-0644(14)00223-6 We (...) compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting. A prospective, randomized, double-blind, placebo-controlled trial was conducted in 2 metropolitan EDs in Melbourne, Australia. Eligible patients with ED nausea and vomiting were randomized to receive 4 mg intravenous ondansetron, 20 mg intravenous metoclopramide, or saline solution placebo. Primary outcome was mean change in visual analog scale (VAS) rating

EvidenceUpdates2014

11. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial

Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial 24807340 2014 05 22 2014 07 14 2014 05 22 1873-233X 123 6 2014 Jun Obstetrics and gynecology Obstet Gynecol Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. 1272-9 10.1097/AOG.0000000000000242 To compare ondansetron with metoclopramide in the treatment of hyperemesis gravidarum. We enrolled 160 women with hyperemesis gravidarum in a double-blind (...) randomized trial. Participants were randomized to intravenous 4 mg ondansetron or 10 mg metoclopramide every 8 hours for 24 hours. Participants kept an emesis diary for 24 hours; at 24 hours, they expressed their well-being using a 10-point visual numeric rating scale and answered an adverse effects questionnaire. Nausea intensity was evaluated using a 10-point visual numeric rating scale at enrollment and at 8, 16, and 24 hours. Primary analysis was on an intention-to-treat basis. Eighty women each were

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

12. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea 24334242 2014 09 03 2014 11 07 2016 12 15 1468-3288 63 10 2014 Oct Gut Gut A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. 1617-25 10.1136/gutjnl-2013-305989 Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven (...) effective but have serious side effects. Ondansetron, also a 5-HT3RA, has been widely used as an antiemetic with an excellent safety record for over two decades. Our aim was to assess its effectiveness in IBS-D. 120 patients meeting Rome III criteria for IBS-D entered a randomised, double-blind, placebo-controlled crossover study of 5 weeks of ondansetron 4 mg versus placebo with dose titration allowed, up to two tablets three times daily in the first 3 weeks. Patients completed daily diaries

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

13. Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines

Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions

Health Technology Assessment (HTA) Database.2014

14. Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety

Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation CADTH. Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One randomized controlled trial was identified regarding the clinical effectiveness and harms of intravenous (IV) ondansetron for the prevention and treatment of post-operative nausea and vomiting in elderly patients. Final publication URL Indexing

Health Technology Assessment (HTA) Database.2014

15. Long-term use of ondansetron, dolasetron and granisetron for the prevention of nausea and vomiting: a review of the clinical effectiveness and safety

Long-term use of ondansetron, dolasetron and granisetron for the prevention of nausea and vomiting: a review of the clinical effectiveness and safety Long-term use of ondansetron, dolasetron and granisetron for the prevention of nausea and vomiting: a review of the clinical effectiveness and safety Long-term use of ondansetron, dolasetron and granisetron for the prevention of nausea and vomiting: a review of the clinical effectiveness and safety CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long-term use of ondansetron, dolasetron and granisetron for the prevention of nausea and vomiting: a review of the clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions No evidence regarding the efficacy and safety of the long-term use

Health Technology Assessment (HTA) Database.2014

16. Ondansetron

Ondansetron USE OF ONDANSETRON IN PREGNANCY 0344 892 0909 USE OF ONDANSETRON IN PREGNANCY (Date of issue: April 2015 , Version: 2.3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Ondansetron is a selective 5HT3 serotonin antagonist used (...) in the treatment of chemotherapy-induced and post-operative nausea and vomiting, and off-licence for nausea and vomiting in pregnancy (NVP). Data on possible fetal effects of ondansetron exposure in pregnancy are limited. A single published study and a conference abstract both report an approximate 2-fold increase in risk of cardiac defects following first trimester exposure to ondansetron, however both studies include very few pregnancies where exposure occurred prior to 10 weeks and conclusions regarding

UK Teratology Information Service2014

19. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Efficacy of oral ondansetron in t... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1993 ) Volume: 118 , Issue: 6 , Pages: 407-413 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To evaluate the efficacy and safety of oral (...) ondansetron (Zofran) as an antiemetic in patients receiving cyclophosphamide-based chemotherapy. DESIGN: A multicenter, randomized, double-blind, stratified, placebo-controlled trial conducted between March 1989 and January 1990. SETTING: Twenty-seven oncology centers including university hospitals, community cancer centers, and private medical oncology practices. PATIENTS: A total of 349 chemotherapy-naive patients having their first cycle of cyclophosphamide or = 450 mg/m2)-based chemotherapy. Patients

Annals of Internal Medicine2013

20. Ondansetron for intravenous use: posology in patients age 65 years or older

Ondansetron for intravenous use: posology in patients age 65 years or older Ondansetron for intravenous use: posology in patients age 65 years or older Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ondansetron for intravenous use: posology in patients age 65 years or older From: Published: 7 August 2013 Therapeutic area: and New advice on dilution and administration in patients age 65 years or older refers only to the indication for prevention of chemotherapy (...) -induced nausea and vomiting. Article date: August 2013 We would like to make you aware that on 24 July 2013 we updated the information in the recent intravenous ondansetron posology article published in the . The article was updated to clarify that the new advice on dilution and administration in patients age 65 years or older refers only to the indication for prevention of chemotherapy-induced nausea and vomiting; there has been no change to the dosing, dilution, or administration instructions

MHRA Drug Safety Update2013